Psilocybin Plus Therapy Shows Promise for Depression in Completed Clinical Trial
60-person study tested psilocybin alone and with CBT for major depression, measuring brain activity and inflammatory markers.
Summary
A completed clinical trial at Khyber Medical University tested whether psilocybin mushroom compounds could help treat major depression. Sixty participants received either psilocybin alone, cognitive behavioral therapy, or both treatments combined while continuing their regular antidepressants. Researchers measured depression symptoms, brain electrical activity, inflammation levels, and neuroplasticity markers to see which approach worked best. The study ran for eight months and represents growing research into psychedelic-assisted therapy for mental health conditions that often accompany aging and chronic disease.
Detailed Summary
A groundbreaking clinical trial at Khyber Medical University has completed testing psilocybin, the active compound in magic mushrooms, as a treatment for major depressive disorder. The study aimed to determine whether psilocybin alone or combined with cognitive behavioral therapy could improve depression outcomes beyond standard care.
The randomized controlled trial enrolled 60 participants with major depressive disorder over an eight-month period from December 2024 to July 2025. Participants were divided into groups receiving psilocybin-only therapy, traditional CBT, or psilocybin-assisted CBT while continuing their routine depression medications.
Researchers measured comprehensive outcomes including depression symptom scores, neurochemical markers, inflammatory markers, and neuroplasticity indicators. They also assessed brain electrical activity patterns using validated neurological testing tools to understand how treatments affected brain function at multiple levels.
While specific results await publication, this completed trial adds to mounting evidence that psychedelic compounds may offer new therapeutic pathways for treatment-resistant depression. The study's comprehensive approach measuring both psychological symptoms and biological markers provides valuable data on how psilocybin affects brain health and inflammation.
For longevity-focused individuals, this research is particularly relevant since depression significantly impacts healthspan and is linked to accelerated aging, chronic inflammation, and increased disease risk. Understanding how novel treatments like psilocybin therapy might address both mental health and underlying biological processes could inform future integrative approaches to healthy aging and cognitive wellness.
Key Findings
- Completed trial tested psilocybin alone versus combined with CBT in 60 depression patients
- Study measured brain activity, inflammation, and neuroplasticity alongside depression symptoms
- Participants continued standard antidepressants while receiving experimental treatments
- Eight-month trial provides comprehensive data on psychedelic-assisted therapy outcomes
Methodology
Randomized controlled trial with 60 participants over 8 months comparing three treatment arms: psilocybin-only, CBT-only, and combined psilocybin-assisted CBT. All participants maintained their existing depression medications throughout the study period.
Study Limitations
Small sample size of 60 participants limits generalizability to broader populations. Concurrent use of standard antidepressants makes it difficult to isolate psilocybin's specific effects. Results and safety data are not yet published for full evaluation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.